Technetium Exametazime
Technetium exametazime (99mTc-HMPAO) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is retained in brain tissue proportional to regional cerebral blood flow, enabling SPECT perfusion imaging of the brain. It is also used to radiolabel white blood cells for scintigraphic detection of infection and inflammation. Brain SPECT with this agent is used in the evaluation of dementia, cerebrovascular disease, and psychiatric disorders.
Moleküler Ağırlık
384,2700 g/mol
TPSA
87,10 Ų
Etki Mekanizması
Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.
SMILES
C[C@H](/C(=N/O)/C)[N-]CC(C)(C)C[N-][C@H](C)/C(=N/[O-])/C.O=[99Tc+3]
InChI
InChI=1S/C13H26N4O2.O.Tc/c1-9(11(3)16-18)14-7-13(5,6)8-15-10(2)12(4)17-19;;/h9-10,18-19H,7-8H2,1-6H3;;/q-2;;+3/p-1/b16-11+,17-12+;;/t9-,10-;;/m1../s1/i;;1+1
Molecular Formula
C13H25N4O3Tc
HBD / HBA
1 / 7
Döndürülebilir Bağlar
0
Ağır Atomlar
21
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
Technetium exametazime (99mTc-HMPAO) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is retained in brain tissue proportional to regional cerebral blood flow, enabling SPECT perfusion imaging of the brain. It is also used to radiolabel white blood cells for scintigraphic detection of infection and inflammation. Brain SPECT with this agent is used in the evaluation of dementia, cerebrovascular disease, and psychiatric disorders.
Contains a radioactive isotope that accumulates in specific tissues or organs, enabling detection and imaging of physiological processes or pathological conditions using nuclear medicine techniques.
Yes, Technetium Exametazime is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2111018. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 129626367. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="technetium-exametazime"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/technetium-exametazime/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/technetium-exametazime/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/technetium-exametazime/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="technetium-exametazime"></drugfyi-drug>